Teneligliptin + Metformin Tablets

Mechanism

Teneligliptin inhibits DPP‑4 enzyme, prolonging incretin activity (GLP‑1, GIP), which increases insulin secretion and reduces glucagon release. Metformin decreases hepatic glucose production and improves peripheral insulin sensitivity. Together, they provide complementary glycemic control.

Pharmacokinetics

• Teneligliptin Absorption: Rapidly absorbed; peak plasma concentration in 1–2 hours.
• Teneligliptin Bioavailability: ~85% oral bioavailability.
• Teneligliptin Half-life: ~20–24 hours, supporting once‑daily dosing.
• Metformin Absorption: Sustained release formulation provides gradual absorption; Tmax ~4–8 hours.
• Metformin Bioavailability: ~50–60%; reduced with food.
• Metformin Distribution: Negligible protein binding; widely distributed.
• Metformin Excretion: Eliminated unchanged via kidneys; half‑life ~6 hours.

Side Effects

• Hypoglycemia (rare, usually with other agents)
• Gastrointestinal upset (nausea, diarrhea)
• Headache
• Lactic acidosis (rare, with metformin)

Contraindication

• Severe renal impairment
• Severe hepatic impairment
• Hypersensitivity to either component

Interaction

• CYP3A4 inhibitors/inducers (affect Teneligliptin levels)
• Alcohol (increases risk of lactic acidosis with Metformin)
• Other antidiabetic agents (risk of hypoglycemia)

Warning and Precautions

• Use under medical supervision only
• Monitor renal and hepatic function regularly
• Adjust dose in elderly patients

Dosage

As directed by the Physician.